- The FDA has accepted ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) supplemental marketing application for Purified Cortrophin Gel.
- The application seeks approval for multiple indications, including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome.
- Prescription Drug User Fee Act’s target action date is October 29.
- Related content: Benzinga’s Full FDA Calendar.
- Price Action: ANIP shares are 11.20% at $30.46 during the premarket session on the last check Tuesday.
BMO Capital Initiates Coverage On Brown & Brown with Outperform Rating, Announces Price Target of $67
BMO Capital analyst Michael Zaremski initiates coverage on Brown & Brown (NYSE:BRO) with a Outperform rating and announces Price Target of $67.
